Literature DB >> 17047057

Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition.

Terence K Lee1, Kwan Man, Ronnie T P Poon, Chung Mau Lo, Anthony P Yuen, Irene O Ng, Kevin T Ng, Warren Leonard, Sheung Tat Fan.   

Abstract

Poor prognosis of hepatocellular carcinoma (HCC) is associated with a high potential of vascular invasion and metastasis. Epithelial-mesenchymal transition (EMT) is a key event in the tumor invasion process. Recently, signal transducers and activators of transcription 5 (STAT5) has been linked to tumor progression by EMT induction. However, the precise roles of STAT5 genes (STAT5a and STAT5b) in human epithelial cancers have not been elucidated clearly. The aim of this study is to analyze the roles of STAT5 isoforms in HCC progression using HCC clinical samples. We showed that activation of STAT5b, but not STAT5a, was found in HCC clinical samples and its expression was significantly associated with younger age (P = 0.037), advanced tumor stages (P = 0.003), venous infiltration (P = 0.016), microsatellite formation (P = 0.024), multiple tumor nodules (P = 0.02), and poor patient survival. To specifically investigate the mechanism underlying constitutive activation of STAT5b in HCC, EGFP-HBX was introduced into Huh-7 cells. STAT5b activation in HCC is at least partially mediated by HBX activation. Ectopic STAT5b transfection conferred increased HCC cell motility and invasiveness by induction of EMT changes. In conclusion, STAT5b activation enhanced HCC aggressiveness by induction of EMT, which was possibly mediated by HBX activation. STAT5b could serve as a novel molecular target for HCC treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047057     DOI: 10.1158/0008-5472.CAN-06-1092

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Epithelial-mesenchymal transitions and hepatocarcinogenesis.

Authors:  Janice Jou; Anna Mae Diehl
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

2.  Expression of phosphorylated Stat5 predicts expression of cyclin D1 and correlates with poor prognosis of colonic adenocarcinoma.

Authors:  Yinling Mao; Zhiwei Li; Changjie Lou; Yanqiao Zhang
Journal:  Int J Colorectal Dis       Date:  2010-11-16       Impact factor: 2.571

3.  Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.

Authors:  Khatri Latha; Ming Li; Vaibhav Chumbalkar; Anupama Gururaj; YeoHyeon Hwang; Sumana Dakeng; Raymond Sawaya; Kenneth Aldape; Webster K Cavenee; Oliver Bogler; Frank B Furnari
Journal:  Int J Cancer       Date:  2012-07-09       Impact factor: 7.396

4.  STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.

Authors:  Christian Moser; Petra Ruemmele; Sebastian Gehmert; Hedwig Schenk; Marina P Kreutz; Maria E Mycielska; Christina Hackl; Alexander Kroemer; Andreas A Schnitzbauer; Oliver Stoeltzing; Hans J Schlitt; Edward K Geissler; Sven A Lang
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

5.  Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence.

Authors:  Gudrun Zulehner; Mario Mikula; Doris Schneller; Franziska van Zijl; Heidemarie Huber; Wolfgang Sieghart; Bettina Grasl-Kraupp; Thomas Waldhör; Markus Peck-Radosavljevic; Hartmut Beug; Wolfgang Mikulits
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

6.  Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: Clinical significance of transforming growth factor-β signaling.

Authors:  Kosuke Mima; Hiromitsu Hayashi; Hideyuki Kuroki; Shigeki Nakagawa; Hirohisa Okabe; Akira Chikamoto; Masayuki Watanabe; Toru Beppu; Hideo Baba
Journal:  Oncol Lett       Date:  2012-10-05       Impact factor: 2.967

7.  Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.

Authors:  Natini Jinawath; Chanont Vasoontara; Artit Jinawath; Xueping Fang; Kejia Zhao; Kai-Lee Yap; Tong Guo; Cheng S Lee; Weijie Wang; Brian M Balgley; Ben Davidson; Tian-Li Wang; Ie-Ming Shih
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

8.  ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway.

Authors:  Tatiana Vignudelli; Tommaso Selmi; Andrea Martello; Sandra Parenti; Alexis Grande; Claudia Gemelli; Tommaso Zanocco-Marani; Sergio Ferrari
Journal:  Mol Biol Cell       Date:  2010-08-11       Impact factor: 4.138

9.  Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting.

Authors:  Priya Koppikar; Vivian Wai Yan Lui; David Man; Sichuan Xi; Raymond Liu Chai; Elizabeth Nelson; Allison B J Tobey; Jennifer Rubin Grandis
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

10.  Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation.

Authors:  Atsushi Hosui; Akiko Kimura; Daisuke Yamaji; Bing-mei Zhu; Risu Na; Lothar Hennighausen
Journal:  J Exp Med       Date:  2009-03-30       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.